Corcept Therapeutics Announces Extension of Previously Announced Tender Offer
December 08, 2021 08:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”) a commercial-stage company engaged in the discovery and development of drugs to...
Corcept Therapeutics to Present at Upcoming Investor Conferences
November 10, 2021 08:30 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics Announces Commencement of Tender Offer to Purchase up to 10 Million Shares of its Common Stock
November 08, 2021 08:30 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) (“Corcept”) a commercial-stage company engaged in the discovery and development of drugs to...
Corcept Therapeutics Announces Third Quarter Financial Results And Provides Corporate Update
November 03, 2021 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call
October 27, 2021 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Oct. 27, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report third quarter financial results and provide a corporate update...
Positive Results Presented at ESMO 2021 From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients with Recurrent Platinum-Resistant Ovarian Cancer
September 17, 2021 08:30 ET
|
Corcept Therapeutics Incorporated
Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial featured in a proffered paper oral presentation at ESMO 2021Results show statistically significant and clinically relevant...
Corcept Announces Presentation of Positive Results From Randomized, Controlled, Phase 2 Trial of Relacorilant in Patients With Recurrent Platinum-Resistant Ovarian Cancer at ESMO 2021
September 09, 2021 16:05 ET
|
Corcept Therapeutics Incorporated
Data from Corcept’s 178-patient, randomized, controlled, Phase 2 trial to be featured in a proffered paper oral presentation at the upcoming ESMO conference on September 17, 2021Results show benefit...
William Guyer to join Corcept as Chief Development Officer
August 12, 2021 17:00 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update
July 29, 2021 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., July 29, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of drugs to treat severe...
Corcept Therapeutics To Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call
July 22, 2021 16:05 ET
|
Corcept Therapeutics Incorporated
MENLO PARK, Calif., July 22, 2021 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report second quarter financial results and provide a corporate update...